A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes

Phase 3 Completed 354 enrolled Eli Lilly and Company

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to see if LY900014 compared to insulin lispro (Humalog), both in combination with insulin glargine or insulin degludec, is safe and effective in participants with type 1 diabetes (T1D).

Timeline

Start: 2019-05-29
Primary completion: 2022-01-10
Completion: 2022-01-10

Publications

Ma J, Yan X, Feng Q, Liu W, Perez Manghi F, Garcia-Hernandez P, Wang G, Xu J, Yuan Y, Zhou Z. Ultra-rapid lispro improved postprandial glucose control compared to insulin lispro in predominantly Chinese patients with type 1 diabetes: A prospective, randomized, double-blind phase 3 study. Diabetes Obes Metab. 2024 Jan;26(1):311-318. doi: 10.1111/dom.15317. Epub 2023 Oct 23.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Insulin Lispro	Protein / enzyme biologic	—	Subcutaneous
Background	insulin degludec	Protein / enzyme biologic	—	Subcutaneous
Background	insulin glargine	Protein / enzyme biologic	—	Subcutaneous

A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes

Summary

Timeline

Publications

Drugs

Indications